[SCHEDULE 13G/A] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) Schedule 13G/A reports that BioDiscovery 6 FPCI, Andera Partners and two Andera managing partners, Stephane Bergez and Francois Xavier Mauron, together may be deemed to beneficially own 2,765,976 shares of common stock, representing 4.2% of the class based on 65,175,287 shares outstanding as of May 8, 2025. The shares are held of record by BioDiscovery 6; voting and dispositive authority is shared (no sole voting or dispositive power reported). The filers disclaim status as a group. The filing discloses Paris as the reporting persons' principal address and includes a joint filing agreement as an exhibit.

Insights

Financial Analyst

TL;DR: A non-U.S. investor group reports a sub-5% passive stake (4.2%) in Mineralys with shared voting/dispositive power.

The Schedule 13G/A shows a passive ownership position below the 5% threshold, which generally indicates non-control intent under SEC reporting categories. The economic exposure of 2,765,976 shares is disclosed with shared voting and dispositive authority, implying control of record shares rests with BioDiscovery 6 while Andera's management participates in decisions. Given the 4.2% stake, this disclosure is informational and unlikely to trigger material changes in governance or financing dynamics absent subsequent increases in position or coordination.

Corporate Governance Expert

TL;DR: Reporting parties disclose shared authority but disclaim a formal group; no evidence of change-in-control intent.

The filing's certification states the securities were not acquired to influence control, consistent with Schedule 13G treatment. Shared voting and dispositive power via the management company is clearly noted, and the explicit disclaimer of group status reduces immediate governance concerns. Investors should view this as enhanced transparency about ownership structure rather than an activist or control-driven disclosure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MINERALYS THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

603170101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 603170101

1

Names of Reporting Persons

Andera Partners

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,765,976.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,765,976.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,765,976.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 603170101

1

Names of Reporting Persons

BioDiscovery 6 FPCI

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,765,976.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,765,976.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,765,976.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 603170101

1

Names of Reporting Persons

Stephane Bergez

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,765,976.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,765,976.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,765,976.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 603170101

1

Names of Reporting Persons

Francois Xavier Mauron

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,765,976.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,765,976.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,765,976.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MINERALYS THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 150 N. Radnor Chester Road, Suite F200, Radnor, PA, 19087.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 2 place de Rio de Janeiro 75008 Paris France
(c)	Citizenship: BioDiscovery 6 France Andera France Bergez France Mauron France
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 603170101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. BioDiscovery 6 is the record holder of 2,765,976 shares of common stock. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 65,175,287 shares of common stock outstanding as of May 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Andera Partners

Signature:	/s/ Stephane Bergez
Name/Title:	By Stephane Bergez, Managing Partner
Date:	08/14/2025

BioDiscovery 6 FPCI

Signature:	/s/ Stephane Bergez
Name/Title:	By Andera Partners, its management company, By Stephane Bergez, Managing Partner
Date:	08/14/2025

Stephane Bergez

Signature:	/s/ Stephane Bergez
Name/Title:	Stephane Bergez
Date:	08/14/2025

Francois Xavier Mauron

Signature:	/s/ Francois Xavier Mauron
Name/Title:	Francois Xavier Mauron
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

What stake in Mineralys Therapeutics (MLYS) is reported in this Schedule 13G/A?

The filers report beneficial ownership of 2,765,976 shares, equal to 4.2% of the outstanding common stock based on 65,175,287 shares outstanding as of May 8, 2025.

Who are the reporting persons on this filing for MLYS?

The reporting persons are BioDiscovery 6 FPCI, Andera Partners, and individuals Stephane Bergez and Francois Xavier Mauron.

Do the filers claim they form a group or intend to influence control of MLYS?

No. The filers expressly disclaim group status and certify the securities were not acquired to change or influence control of the issuer.

What voting and dispositive powers are disclosed by the filers?

The filing reports 0 sole voting power and 0 sole dispositive power, with 2,765,976 shares reported as shared voting and shared dispositive power.

Where is the reporting party located and is there an exhibit attached?

The reporting persons list their principal business address in Paris, France, and the filing includes Exhibit 99.1: Joint Filing Agreement.